An Early Detection of Cancer and Prediction of Tissue of Origin with PredOmix OncoVeryx© to confirm Precision and/or Accuracy in Cancer and Non-Cancerous Population: A Prospective Trial of OncoVeryx© for Early Detection of Cancer and Prediction of Tissue of Origin - Nil

MS Clinfinite Solutions0 个研究点目标入组 0 人开始时间: 待定最近更新: 2024年6月24日

试验速览

暂无简介。

•1. Subjects who voluntarily participate in this study by signing their Informed Consent Form
•(ICF) in the local language prior to any study-mandated procedure.
•2. Males or females aged = 18 years at time of signing the ICF.
•3. Group 1:
•i. Subjects who are diagnosed with or suspected to have any cancer type.
•ii. Subjects must be treatment naive [i.e., should not have history of any chemotherapy, immunotherapy, radiotherapy etc.,].

•1. Currently participating in another investigational study.
•2. Female subjects who are pregnant
•3. Subjects with either high-grade dysplasia, autoimmune disease, or chronic kidney disease.
•4. Subjects has a condition that, in the opinion of the investigator, would preclude participation in the study.

发起方

MS Clinfinite Solutions